Get the Stockscreener App
32.24
3.07%
-1.02
After Hours:
32.51
0.27
+0.84%
Tg Therapeutics Inc stock is traded at $32.24, with a volume of 1.76M.
It is down -3.07% in the last 24 hours and down -11.67% over the past month.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
See More
Previous Close:
$33.26
Open:
$33.42
24h Volume:
1.76M
Relative Volume:
0.87
Market Cap:
$5.12B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-293.09
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
-7.30%
1M Performance:
-11.67%
6M Performance:
-7.49%
1Y Performance:
+15.56%
1-Day Range:
$31.98
$33.51
1-Week Range:
$31.07
$36.50
52-Week Range:
$25.28
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
32.24 | 5.28B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Resumed | H.C. Wainwright | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Oct-29-24 | Initiated | TD Cowen | Buy |
| Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-26-23 | Resumed | Jefferies | Buy |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-01-20 | Initiated | JP Morgan | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Initiated | Evercore ISI | Outperform |
| Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
| Nov-14-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-17 | Initiated | Jefferies | Buy |
| Mar-06-17 | Reiterated | FBR & Co. | Outperform |
| Oct-06-16 | Resumed | Brean Capital | Buy |
| May-27-16 | Initiated | SunTrust | Buy |
| Dec-01-15 | Initiated | FBR Capital | Outperform |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| Aug-12-15 | Resumed | H.C. Wainwright | Buy |
| Jun-19-15 | Reiterated | Brean Capital | Buy |
| Dec-11-14 | Reiterated | ROTH Capital | Buy |
| Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
Will TG Therapeutics Inc. stock benefit from commodity pricesQuarterly Profit Report & Long-Term Investment Growth Plans - newser.com
TG Therapeutics (TGTX) Earnings Date and Reports 2025 - MarketBeat
Will TG Therapeutics Inc. stock outperform value stocks2025 Major Catalysts & Reliable Entry Point Trade Alerts - newser.com
How TG Therapeutics Inc. stock compares to industry benchmarksWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
TG Therapeutics (TGTX) Financials 2025Income Statement and Balance Sheet - MarketBeat
TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo Finance
TG Therapeutics (TGTX) Stock Price, News & Analysis - MarketBeat
Highly Watched TG Therapeutics Smashes Profit Views — But There's A Caveat - MSN
Analyzing recovery setups for TG Therapeutics Inc. investorsRate Hike & Low Drawdown Investment Strategies - newser.com
What Wall Street predicts for TG Therapeutics Inc. stock priceTrade Analysis Report & Safe Capital Growth Trade Ideas - fcp.pa.gov.br
How to escape a deep drawdown in TG Therapeutics Inc.2025 Market Outlook & Technical Pattern Alert System - newser.com
What dividend safety score for TG Therapeutics Inc. stockBond Market & Long Hold Capital Preservation Tips - newser.com
How TG Therapeutics Inc. (NKB2) stock trades under stagflationBond Market & Long-Term Growth Plans - newser.com
Building trade automation scripts for TG Therapeutics Inc.Trade Performance Summary & Low Volatility Stock Suggestions - newser.com
How to build a dashboard for TG Therapeutics Inc. stockWeekly Market Report & AI Powered Buy and Sell Recommendations - newser.com
Is it time to cut losses on TG Therapeutics Inc.Earnings Overview Summary & AI Driven Stock Movement Reports - newser.com
TG Therapeutics, Inc. (TGTX) Stock forecasts - Yahoo! Finance UK
Decoding TG Therapeutics Inc (TGTX): A Strategic SWOT Insight - GuruFocus
Can TG Therapeutics Inc. stock resist market sell offsJuly 2025 Big Picture & Safe Capital Growth Trade Ideas - newser.com
What technical charts say about TG Therapeutics Inc. stockJuly 2025 Rallies & Weekly High Momentum Picks - fcp.pa.gov.br
Is TG Therapeutics Inc. stock gaining market shareNew Guidance & High Accuracy Trade Signal Alerts - newser.com
Why TG Therapeutics (TGTX) is a Top Growth Stock for the Long-Term - sharewise.com
TG Therapeutics Earns Membership In 95-Plus Composite Rating Club - MSN
Is TG Therapeutics Inc. stock oversold or undervaluedJuly 2025 Levels & Low Drawdown Momentum Ideas - newser.com
Is TG Therapeutics Inc. stock a good choice for value investors2025 Short Interest & High Accuracy Trade Signal Alerts - newser.com
Tools to assess TG Therapeutics Inc.’s risk profileWeekly Trade Analysis & Safe Swing Trade Setups - newser.com
Is now a turning point for TG Therapeutics Inc.Quarterly Trade Review & Short-Term High Return Strategies - newser.com
TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug - MSN
Will TG Therapeutics Inc. stock attract ESG investorsGap Down & Weekly Market Pulse Updates - newser.com
TG Therapeutics (TGTX) Margin Miss Challenges Growth-Driven Profitability Narrative - Yahoo Finance
TG Therapeutics (NASDAQ:TGTX) Given New $49.00 Price Target at JPMorgan Chase & Co. - MarketBeat
TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised - Yahoo Finance
TG Therapeutics (TGTX): Exploring Valuation as Growth Prospects Spark Investor Interest - Yahoo Finance
TG Therapeutics (NASDAQ:TGTX) Announces Quarterly Earnings Results, Beats Estimates By $2.19 EPS - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2025 Earnings Call Transcript - Insider Monkey
Hussman Strategic Advisors Inc. Grows Position in TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics: Q3 Earnings Snapshot - theheraldreview.com
HC Wainwright Predicts Reduced Earnings for TG Therapeutics - MarketBeat
TG Therapeutics (TGTX) 10K Form and SEC Filings 2025 - MarketBeat
TG Therapeutics Earnings Notes - Trefis
JP Morgan Maintains TG Therapeutics (TGTX) Overweight Recommendation - MSN
TG Therapeutics Reports Strong Q3 2025 Results - The Globe and Mail
TG Therapeutics raises BRIUMVI 2025 revenue guidance to $585M while advancing subcutaneous pipeline - MSN
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):